OmniAb, Inc.

OmniAb, Inc. (OABIW) has generated zero cyber incidents and zero red-flag 8-K filings in our 90-day monitoring window, indicating surface-level operational stability over the recent period. However, low signal in a three-month window does not indicate low structural risk; biotech warrant securities face distinct pressures around dilution, financing runway, and clinical pipeline execution that require deeper context. The full $49 Report extends analysis to 12 months of SEC filings, calculates dilution risk scores across equity structures, maps financing history and cash burn patterns, and flags emerging AI-related disclosure risks specific to the therapeutics sector. The full $49 Report adds quantified dilution metrics, 12-month filing context, and forward risk signals that a short window cannot capture.